Company Update

Further to the Company's recent market update announcing significant improvement in H1 EBITDA and gross margin, confirming the turnaround trajectory remains on track, the Board provides the following update regarding various financing solutions under consideration.

The Company has received unsolicited preliminary interest from separate parties regarding the acquisition of Pain Away and other assets. Early-stage due diligence is underway across both approaches.

Additionally, a syndicate has approached the Company with an indicative early-stage proposal to provide convertible note funding to expand Pain Away into Asia and North America, aligned with the Company's strategy of delivering positive free cash flow, profitability and long-term shareholder value.

Financing Evaluation

The Board is actively assessing these opportunities alongside traditional debt and equity options to secure the optimal capital structure to maximise value for all shareholders, to settle former director loan repayments due in April 2026 and to drive the turnaround in the business and Pain Away brand.

The Company will provide further updates in accordance with its continuous disclosure obligations under ASX Listing Rules and AIM Regulation. There can be no certainty that any or all of the potential transactions outlined above will proceed to completion or as to the terms of any transaction Any potential transaction will be assessed against applicable regulatory requirements.